Abbott to split off branded pharma unit, pursue specialty drug focus

Share this article:

Abbott said today it will separate into two publicly traded companies, one its $18-billion pharma unit and the other its $22-billion diversified medical products business.

The research-based pharmaceutical company, which has yet to be named, will be led by 30-year Abbott veteran Richard Gonzalez, currently EVP for global pharmaceuticals. It will focus on “select specialty products” Abbott said.

The drug portfolio includes brands such as blockbuster rheumatoid arthritis biologic Humira, along with Lupron, Synagis, Kaletra, Creon and Synthroid. Its pipeline has agents in hepatitis C, immunology, chronic kidney disease, women's health, oncology and neuroscience. The majority of revenue will continue to come from developed markets.

The diversified medical products company, to be led by current Abbott chairman and CEO Miles White, is retaining the Abbott name. It will focus on devices like heart stents and will have an extensive, broad-based pipeline of new products and technologies, Abbott said, while it will generate nearly 40% of sales in high-growth emerging markets.

The transaction is expected to be completed by the end of next year, but is subject to final approval by the Abbott board of directors.

In a note to investors about the spin-off, Credit-Suisse's Catherine Arnold said Abbott's decision to split branded pharmaceuticals from its diversified business “may suggest divergence in outlook. We see the pharma business entering a slower growth, higher risk profile business, while the diversified business may have margin expansion potential and pending success of emerging market, higher growth.”

Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.